BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Janssen-Cilag  International  NV  submitted  on  04  January  2006  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  PREZISTA,  through  the 
centralised  procedure  falling  within  the  Article  3(1)  and  point  3  of  Annex  of  Regulation  (EC)  No 
726/2004.  The  eligibility  to  the  centralised  procedure  was  agreed  upon  by  the  EMEA/CHMP  on  27 
July 2005 and re-confirmed on 15 December 2005. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 23 May 2003 and 21 January 2005. The 
Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier.  
Licensing status: 
PREZISTA has been given a Marketing Authorisation in the United States on 23 June 2006, in Canada 
on 28 July 2006, in Russia on 22 September 2006, and in Argentina on 30 November 2006. 
A  new  application  was  filed  in  the  following  countries:  Turkey,  Australia,  Mexico,  New  Zealand, 
Taiwan, Singapore, Israel and Hong Kong SAR 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: 
B. van Zwieten-Boot  
Co-Rapporteur: 
I. Hudson  
2 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 04 January 2006. 
Accelerated assessment procedure was rejected by the CHMP on 26 January 2006. 
The procedure started on 01 February 2006.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  19  April 
2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 31 
March 2006. In accordance with Article 6(3) of Regulation (RC) No 726/2004, the Rapporteur 
and  Co-Rapporteur  declared  that  they  had  completed  their  assessment  report  in  less  than  80 
days.   
During the meeting on 1st June 2006, the CHMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 
2 June 2006. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 8 August 
2006. 
The  Rapporteurs  circulated  the  Joint  Assessment  Report  on  the  applicant’s  responses  to  the 
CHMP List of Questions to all CHMP members on 22 September 2006 and 26 September 2006. 
During  the  CHMP  meeting  on  18  October  2006,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues on 14 November 
2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the list 
of outstanding issues provided by the applicant on 1st December 2006  
During the meeting in December 2006, the CHMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
conditional  Marketing  Authorisation  to  PREZISTA  on  14  December  2006.  The  applicant 
provided  the  letter  of  undertaking  on  the  specific  obligations  and  follow-up  measures  to  be 
fulfilled post-authorisation on 14 December 2006. 
1/1 
©EMEA 2006 
 
 
 
 
 
 
 
 
 
 
